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differences among the patients that could be explained by individual 
radiosensitivity. 
Materials and Methods: The salivary gland ejection (excretion) 
fraction (sEF) was measured by Tc-99m pertechnetate scintigraphy for 
50 patients receiving IMRT for head and neck cancer. The scintigraphy 
was performed before RT and repeated 6 and 12 months after RT. 
Only the glands with Dmean values between 15 Gy and 45 Gy were 
included and the glands which were not functioning properly prior to 
RT were excluded. The relative ejection fraction rEF(t) = sEF(t) / 
sEF(0) was first compared for both parotid glands of the same patient 
at the same time of measurement. Next, the rEF values at 6 and 12 
months after RT were compared for the same gland. To enable the 
comparison of rEF values between glands receiving varying Dmean, the 
mean effect of the absorbed dose on the gland was eliminated. This 
was achieved by dividing the rEF value for the gland with the 
respective value of sigmoidal mean dose response curve for the whole 
group of patients (rEF0=rEF(t)*(1+(Dmean/D50)^k)). Fisher’s exact test 
was used in the analysis with two categories defined by median rEF0. 
Average errors in Dmean values for the glands due to patient positioning 
errors were corrected based on portal images. 
Results: The values for rEF0 ranged from 0 to 2.7. A significant 
association between rEF0 for left and right parotid glands was found 
(χ2=6.0, p<0.025). Some patients show systematically lower or higher 
rEF0 than the median for both parotid glands. This could be explained 
by three possible reasons, as the effect of positioning errors to Dmean 
was excluded: 1) the variations result from the measurement 
technique or 2) the patients react differently to the lemon juice 
stimulus given during the scintigraphy or 3) the post-RT sEF is affected 
by varying individual responses to radiation. The rEF0 values for the 
same gland at 6 and 12 months after RT gave a statistically significant 
relationship between the two variables (χ2=4.73, p≤0.05) (Table 1). 
The same patients had low or high values of rEF0 for both parotid 
glands at both times of measurement. As this behaviour is seen in both 
measurements, it can not be due to fluctuations caused by 
measurement technique. Also, we believe that by using relative values 
instead of single sEF values, we can at least partly overcome the 
problem of patients reacting differently to the stimulus, assuming that 
the factors, such as smoking, that may influence saliva production 
remain the same between the measurements. As a result of this 
indirect deduction, we conclude that the systematic variation in rEF0 
reflects individual differences in radiosensitivity. 
 
 
Conclusions: According to our interpretation the systematic variations 
seen in post-RT salivary gland scintigraphy measurements can be 
explained by individual differences in radiosensitivity. Quantitative 
extraction of individual radiosensitivity requires further studies.  
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Purpose/Objective: Ferrofluid particles being subjected to an 
electromagnetic field show remarkable heating effects related to 
losses during the magnetization process and Joule heating of the 
particles. The temperature enhancement which occurs in a magnetic 
ferrofluid system under the influence of an external high frequency 
magnetic field has found applications in breast tumor hyperthermia 
treatment therapy. The main objectives are the uniformity of the 
temperature distribution and the target value of temperature to be up 
to 42°C in the controlled region for magnetic hyperthermia 
treatment. This temperature control is hard to implement because of 
many tissue individual variations and other therapy conditions. 
Materials and Methods: For determination of the thermal field 
distribution in magnetic hyperthermia therapy, a coupled 
electromagnetic – thermal - fluid dynamics field computational model 
is developed. The electromagnetic field distribution inside the 
conductive tissue region depends on the time varying magnetic flux 
density. The heat sources are defined by the electric losses in tissue, 
acquired by the solution of the electromagnetic field problem. The 
computational model uses anatomically precise multilevel geometrical 
model of human breast with known electrical tissue properties, blood 
and liquor flow speeds in its vessels. Model contains information about 
real cancer structure sample acquired by surgical procedure. Cancer 
and normal electrical tissue properties are directly measured for this 
sample by precise measurement system. 
Results: Sample under treatment is in stage T2N2M1 with maximal 
size of 25 mm. Sample volume is 317 mm3. Ferrofluid solution is 
injected at cancer sample. Ferrofluid filled volume in sample is 24 
mm3. Thermal field distribution in cancer model is presented in Fig.1. 
Maximal temperature acquired is 42.3oC. Temperature maximum 
represents the position of ferrofluid volume. Results from this model 
are validated by infrared thermography measurements of the sample. 
Field values and distributions correspond well to these one acquired 
by the model. 
 Fig.1 Thermal field distribution in tumor model for time period of 
120s. 
 
Conclusions: The coupled electromagnetic-fluid dynamics-thermal 
field computational modeling is capable to predict the magnetic 
ferrofluid hyperthermia thermal effects on live tissue. The developed 
model can be used for therapy planning and also design and 
optimization of interaction between electromagnetic devices and 
biological structures.  
Acknowledgement: This work was supported by the National Science 
Fund of the Ministry of Education and Science of Bulgaria under 
Contract 'D002-157/2008'.  
   
PO-0908   
Identification of a single nucleotide polymorphism associated with 
sexual dysfunction in prostate cancer patients 
J.H. Oh1, R. Stoyanova2, J.O. Deasy1, Z. Saleh1, M.K. Buyyounouski3, 
R.A. Price3, J.J. Hu4, A. Pollack2 
1Memorial Sloan-Kettering Cancer Center, Medical Physics, New York, 
USA  
2University of Miami, Department of Radiation Oncology, Miami, USA  
3Fox Chase Cancer Center, Department of Radiation Oncology, 
Philadelphia, USA  
4University of Miami, Department of Epidemiology and Public Health, 
Miami, USA  
 
Purpose/Objective: To study whether genetic single nucleotide 
polymorphisms (SNPs) are predictive of erectile dysfunction (ED) in 
prostate cancer patients treated with radiotherapy, we investigated 
the relationship between genotypes in SNP data and Expanded 
Prostate Cancer Index Composite (EPIC) scores. 
Materials and Methods: In our previous study, we examined SNPs 
obtained for 124 prostate cancer patients who received radiotherapy 
(RT) and, after identifying a statistically-managable number of SNPs 
using a novel system biology approach, we indentified a single SNP 
(rs2032809) that was statistically associated with post-RT adverse 
 
